Automating TRICARE Specialty Drug Prior Auth Workflows
Klivira streamlines the complex process of TRICARE specialty drug prior auth, ensuring efficient submission and faster approvals for critical therapies.
Revenue cycle leaders and prior authorization teams face unique challenges with TRICARE specialty drug prior auth due to its distinct regulatory framework and benefit structures. Misclassifications and manual processes can lead to significant delays, impacting patient access to high-cost biologics and infusion drugs. Klivira provides a robust solution to navigate these complexities.
Navigating TRICARE Specialty Drug Prior Auth Complexity
TRICARE operates under a specific regulatory framework that dictates prior authorization requirements for specialty drugs, whether administered under the medical or pharmacy benefit. The need for precise benefit-side determination, adherence to unique policy rules, and efficient documentation submission introduces significant operational overhead for clinics and health systems. Klivira recognizes the distinct demands of TRICARE specialty drug prior auth, offering tailored automation to mitigate these challenges.
Common Failure Modes in TRICARE Specialty Drug Prior Auth
- **Benefit-Side Misclassification:** Incorrectly identifying whether a specialty drug falls under the medical or pharmacy benefit for a TRICARE patient, leading to submissions to the wrong channel.
- **Site-of-Care Policy Violations:** Failing to align with TRICARE's site-of-care policies for medical-benefit specialty drugs, which may prefer infusion centers over hospital outpatient settings.
- **Step-Therapy Documentation Gaps:** Inadequate capture of prior-line therapy history required for TRICARE biologic approvals.
- **Specialty Pharmacy Fulfillment Delays:** Post-approval coordination challenges with TRICARE's specialty pharmacy partners, prolonging time-to-medication.
Klivira's Automated Approach to TRICARE Specialty Drug PA
Klivira's platform is engineered to address the specific pain points of specialty drug prior authorization, including those encountered with TRICARE. Our system automates critical steps from benefit-side determination to post-approval coordination, ensuring submissions align with TRICARE's framework and accelerate approval timelines. This minimizes manual effort and reduces the risk of denials stemming from procedural errors.
Klivira's Automated Workflow for TRICARE Specialty Drug Prior Auth
- **Automated Benefit-Side Determination:** Klivira's policy engine accurately identifies if a specialty drug falls under the TRICARE medical or pharmacy benefit, ensuring correct routing.
- **Multi-Channel Submission:** Pharmacy-benefit drugs route via ePA partners (CoverMyMeds, Surescripts) using NCPDP SCRIPT ePA, while medical-benefit drugs utilize channels like X12 278, Da Vinci PAS, or payer portals.
- **Intelligent Step-Therapy Documentation:** The platform extracts medication history and treatment response from FHIR MedicationRequest and Observation resources to fulfill TRICARE's step-therapy requirements.
- **Site-of-Care Policy Alignment:** Klivira integrates site-of-care logic, flagging potential mismatches with TRICARE's policies before submission.
- **Specialty Pharmacy Fulfillment Coordination:** Post-approval, Klivira coordinates the handoff to TRICARE's specialty pharmacy partners, streamlining fulfillment.
Leveraging Industry Standards for TRICARE Submissions
Klivira's platform supports key industry standards crucial for efficient prior authorization, applicable across all payers including TRICARE. This includes NCPDP SCRIPT for pharmacy ePA, FHIR MedicationRequest for clinical data exchange, Da Vinci PAS for medical benefit prior authorization, and X12 278 for EDI submissions. This standards-based approach ensures interoperability and compliance with evolving payer requirements.
Compliance Considerations for TRICARE Specialty Drug PA
Navigating TRICARE's specific regulations for specialty drug prior authorization requires careful attention to compliance. While Klivira automates the submission process and provides robust audit trails, organizations must ensure their internal policies and procedures align with TRICARE's rules and broader healthcare regulations like HIPAA. We recommend discussions with your compliance team to fully understand and implement best practices for TRICARE specialty drug prior auth.
Frequently asked questions
How does Klivira handle the medical vs. pharmacy benefit split for TRICARE specialty drugs?
Klivira's policy engine automatically determines whether a specific specialty drug for a TRICARE patient falls under the medical or pharmacy benefit. This ensures the prior authorization request is routed to the correct channel, preventing common delays caused by misclassification.
Can Klivira help with TRICARE's site-of-care requirements for infused specialty drugs?
Yes, Klivira incorporates site-of-care logic into the PA workflow. For medical-benefit specialty drugs, our system can surface payer policies and flag potential mismatches with TRICARE's preferred sites of care before submission, helping to prevent denials.
What standards does Klivira use for TRICARE specialty drug prior auth submissions?
Klivira leverages industry standards such as NCPDP SCRIPT for pharmacy ePA, FHIR for clinical data, Da Vinci PAS for medical benefit prior authorization, and X12 278 for EDI submissions. This ensures comprehensive connectivity and efficient data exchange with TRICARE and its partners.
How does Klivira improve time-to-medication for TRICARE specialty drug patients?
By automating benefit-side determination, streamlining documentation capture, optimizing submission channels, and coordinating post-approval specialty pharmacy fulfillment, Klivira significantly reduces the administrative burden and associated delays, accelerating patient access to critical TRICARE-covered specialty drugs.
Does Klivira manage manufacturer copay assistance programs for TRICARE patients?
Klivira's workflow identifies the availability of manufacturer copay-assistance programs and flags Medicare-patient exclusions, as manufacturer copay assistance is generally not allowed for Medicare patients due to anti-kickback statute concerns. However, Klivira does not manage program enrollment itself.
Related coverage
Ready to automate prior auth for this line of business?
See how Klivira automates prior authorizations for your team.
Request a demo